610 related articles for article (PubMed ID: 11305417)
1. Importance of dose intensity in neuro-oncology clinical trials: summary report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Anderson CP; Bleyer WA; Cairncross JG; Cloughesy T; Eck SL; Guastadisegni P; Hall WA; Muldoon LL; Patel SJ; Peereboom D; Siegal T; Neuwelt EA
Neuro Oncol; 2001 Jan; 3(1):46-54. PubMed ID: 11305417
[TBL] [Abstract][Full Text] [Related]
2. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium.
Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA
Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607
[TBL] [Abstract][Full Text] [Related]
3. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.
Wong ET
Neurology; 2005 Mar; 64(5):934; author reply 934. PubMed ID: 15753455
[No Abstract] [Full Text] [Related]
4. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting.
Doolittle ND; Abrey LE; Bleyer WA; Brem S; Davis TP; Dore-Duffy P; Drewes LR; Hall WA; Hoffman JM; Korfel A; Martuza R; Muldoon LL; Peereboom D; Peterson DR; Rabkin SD; Smith Q; Stevens GH; Neuwelt EA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):421-8. PubMed ID: 15701824
[TBL] [Abstract][Full Text] [Related]
5. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.
Kroll RA; Neuwelt EA
Neurosurgery; 1998 May; 42(5):1083-99; discussion 1099-100. PubMed ID: 9588554
[TBL] [Abstract][Full Text] [Related]
6. [Role of high-dose chemotherapy with hemopoietic stem-cell support in the treatment of adult patients with high-grade glioma].
Linassier C; Destrieux C; Benboubker L; Alcaraz L; Bergemer-Fouquet AM; Jan M; Calais G; Colombat P
Bull Cancer; 2001 Sep; 88(9):871-6. PubMed ID: 11604360
[TBL] [Abstract][Full Text] [Related]
7. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms.
Williams PC; Henner WD; Roman-Goldstein S; Dahlborg SA; Brummett RE; Tableman M; Dana BW; Neuwelt EA
Neurosurgery; 1995 Jul; 37(1):17-27; discussion 27-8. PubMed ID: 8587686
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of malignant gliomas.
Krauseneck P; Müller B
Recent Results Cancer Res; 1994; 135():135-47. PubMed ID: 7519355
[No Abstract] [Full Text] [Related]
9. Radiochemotherapy of malignant glioma in adults. Clinical experiences.
Kortmann RD; Jeremic B; Weller M; Plasswilm L; Bamberg M
Strahlenther Onkol; 2003 Apr; 179(4):219-32. PubMed ID: 12707711
[TBL] [Abstract][Full Text] [Related]
10. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors.
Finlay JL
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S1-5. PubMed ID: 8971398
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensive ifosfamide for the treatment of non-Hodgkin's lymphoma.
Vose JM
Semin Oncol; 1996 Jun; 23(3 Suppl 6):33-7. PubMed ID: 8677446
[TBL] [Abstract][Full Text] [Related]
12. Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting.
Doolittle ND; Peereboom DM; Christoforidis GA; Hall WA; Palmieri D; Brock PR; Campbell KC; Dickey DT; Muldoon LL; O'Neill BP; Peterson DR; Pollock B; Soussain C; Smith Q; Tyson RM; Neuwelt EA
J Neurooncol; 2007 Jan; 81(1):81-91. PubMed ID: 16858513
[TBL] [Abstract][Full Text] [Related]
13. Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
Pettengell R; Crowther D
Ann Oncol; 1994; 5 Suppl 2():133-41. PubMed ID: 7911317
[TBL] [Abstract][Full Text] [Related]
14. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
15. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL
Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805
[TBL] [Abstract][Full Text] [Related]
16. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
17. Novel chemotherapeutic approaches to brain tumors.
Dropcho EJ
Hematol Oncol Clin North Am; 2001 Dec; 15(6):1027-52. PubMed ID: 11770297
[TBL] [Abstract][Full Text] [Related]
18. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
19. High-dose therapy in breast cancer: out of favor but not out of promise.
Glück S; Stewart D
Bone Marrow Transplant; 2000 May; 25(10):1017-9. PubMed ID: 10828859
[TBL] [Abstract][Full Text] [Related]
20. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
